PHAXIAM Therapeutics
PHAXIAM Therapeutics
PHXM
EURONEXT
1.88
EUR
0.00%
About
PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The company relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
It offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 8.7K |
| Three Month Average Volume | 200.6K |
| High Low | |
| Fifty-Two Week High | 5.54545 EUR |
| Fifty-Two Week Low | 1.64 EUR |
| Fifty-Two Week High Date | 18 Sep 2023 |
| Fifty-Two Week Low Date | 02 Sep 2024 |
| Price and Volume | |
| Current Price | 1.71 EUR |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -13.58% |
| Thirteen Week Relative Price Change | -34.62% |
| Twenty-Six Week Relative Price Change | -31.73% |
| Fifty-Two Week Relative Price Change | -63.63% |
| Year-to-Date Relative Price Change | -60.32% |
| Price Change | |
| One Day Price Change | 1.79% |
| Thirteen Week Price Change | -37.49% |
| Twenty-Six Week Price Change | -34.39% |
| Five Day Price Change | -1.72% |
| Fifty-Two Week Price Change | -61.89% |
| Year-to-Date Price Change | -59.78% |
| Month-to-Date Price Change | 1.79% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 3.89666 EUR |
| Book Value Per Share (Most Recent Quarter) | 3.89666 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.81731 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.81731 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -5.12968 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.26102 EUR |
| Revenue Per Share (Trailing Twelve Months) | 0.29007 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 0 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | 0 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -4.62363 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -5.14182 EUR |
| Normalized (Last Fiscal Year) | -4.67877 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -4.62363 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -5.14182 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -4.62363 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -5.14182 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.59353 EUR |
| Cash Per Share (Most Recent Quarter) | 1.59353 EUR |
| Cash Flow Per Share (Last Fiscal Year) | -4.30728 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | -2.62292 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -99999.99 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1,086 |
| Cash Flow Revenue (Trailing Twelve Months) | -1,859 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,787.10% |
| Pretax Margin (Last Fiscal Year) | -1,787.10% |
| Pretax Margin (5 Year) | -1,007.59% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,784.31% |
| Operating Margin (Trailing Twelve Months) | -1,784.31% |
| Operating Margin (5 Year) | -1,020.45% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,771.42% |
| Net Profit Margin (Trailing Twelve Months) | -1,771.42% |
| Net Profit Margin (5 Year) | -1,009.09% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -44.65% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -83.71% |
| Revenue Growth (3 Year) | -21.50% |
| Revenue Change (Trailing Twelve Months) | -80.05% |
| Revenue Per Share Growth | -35.24% |
| Revenue Growth (5 Year) | -29.08% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -56.68% |
| Total Debt (5 Year) | 73.74% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -106.07% |
| EPS Change (Trailing Twelve Months) | -7,468.18% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 2.8M |
| Net Debt (Last Fiscal Year) | 2.8M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 13 |
| Price to Sales (Trailing Twelve Months) | 13 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | 0.00% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 37 |
| Long Term Debt to Equity (Most Recent Quarter) | 37 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 1 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -24,645,000 |
| Free Cash Flow (Trailing Twelve Months) | -24,645,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -1,095 |
| Net Interest Coverage (Trailing Twelve Months) | -70 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 52 |
| Total Debt to Equity (Most Recent Quarter) | 52 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -48.37% |
| Return on Assets (Trailing Twelve Months) | -48.37% |
| Return on Assets (5 Year) | -50.69% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -95.68% |
| Return on Equity (Trailing Twelve Months) | -95.68% |
| Return on Equity (5 Year) | -87.48% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -66.94% |
| Return on Investment (Trailing Twelve Months) | -66.94% |
| Return on Investment (5 Year) | -66.25% |